Division of Pulmonary and Critical Care Medicine, Daegu Catholic university hospital.
Department of Internal Medicine, School of Medicine, Kyungpook National University.
Medicine (Baltimore). 2021 Feb 19;100(7):e24437. doi: 10.1097/MD.0000000000024437.
To describe the clinical and demographic characteristics of critically ill patients with COVID-19 in Daegu, South Korea, and to explore the risk factors for in-hospital mortality in these patients.Retrospective cohort study of 110 critically ill patients with COVID-19 admitted to the ICU in Daegu, South Korea, between February 18 and April 5, 2020. The final date of follow-up was April 20, 2020.A total of 110 patient medical records were reviewed. The median age was 71 years (interquartile range [IQR] = 63-78 years). During the study period, 47 patients (42.7%) died in the hospital. The most common SARS-CoV-2 infection related complication was acute respiratory distress syndrome (ARDS) in 95 patients (86.4%). Of the 79 patients (71.8%) who received invasive mechanical ventilation, 46 (58.2%) received neuromuscular blockade injection, and 19 (24.1%) received ECMO treatment. All patients received antibiotic injection, 99 patients (90%) received hydroxychloroquine, 96 patients (87.3%) received lopinavir-ritonavir antiviral medication, and 14 patients (12.7%) received other antiviral agents, including darunavir-cobicistat and emtricitabine-tenofovir. In the multivariable logistic regression model, the odds ratio of in-hospital death was higher with APACHE II score (OR = 1.126; 95% CI = 1.014-1.252; P = .027).The in-hospital mortality rate of critically ill patients with COVID-19 was approximately 40%. Higher APACHE II score at admission was an independent risk factor for death in these patients.
描述韩国大邱市 COVID-19 重症患者的临床和人口统计学特征,并探讨这些患者住院死亡率的危险因素。
这是一项回顾性队列研究,纳入了 2020 年 2 月 18 日至 4 月 5 日期间在韩国大邱市 ICU 收治的 110 例 COVID-19 重症患者。随访的最终日期为 2020 年 4 月 20 日。共回顾了 110 例患者的病历。中位年龄为 71 岁(四分位距 [IQR] = 63-78 岁)。研究期间,47 例(42.7%)患者在医院死亡。最常见的 SARS-CoV-2 感染相关并发症是 95 例(86.4%)患者的急性呼吸窘迫综合征(ARDS)。在接受有创机械通气的 79 例患者中(71.8%),46 例(58.2%)接受了神经肌肉阻滞剂注射,19 例(24.1%)接受了 ECMO 治疗。所有患者均接受了抗生素注射,99 例(90%)接受了羟氯喹,96 例(87.3%)接受了洛匹那韦-利托那韦抗病毒药物治疗,14 例(12.7%)接受了其他抗病毒药物治疗,包括达芦那韦-考比司他和恩曲他滨-替诺福韦。在多变量逻辑回归模型中,入院时的急性生理与慢性健康状况评分(APACHE II 评分)越高,住院死亡的比值比(OR)越高(OR = 1.126;95%CI = 1.014-1.252;P = 0.027)。COVID-19 重症患者的院内死亡率约为 40%。入院时较高的 APACHE II 评分是这些患者死亡的独立危险因素。